Search Results

Arbutus Biopharma Corporation today issued the following statement regarding the claim construction ruling of the U.S. District Court for the District of Delaware in the lawsuit brought by Arbutus and its licensee Genevant Sciences (Plaintiffs) against Moderna.

Arbutus Biopharma Corporation today announced that the Arbutus management team will present at and host one-on-one meetings at the following upcoming investor conference being held in New York.

Arbutus Biopharma Corporation announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York.

Suddenly the hottest thing in biopharma isn’t a new indication, disease target or modality—it’s manufacturing, and all of pharma is going to be vying for capacity and talent.

Arbutus Biopharma Corporation announced that two abstracts have been accepted for poster and oral presentations at the European Association for the Study of the Liver Congress 2024 taking place June 5 - 8, 2024 in Milan, Italy.

Arbutus Biopharma Corporation today reports first quarter 2024 financial results and provides a corporate update.

Arbutus Biopharma Corporation announced new preliminary end-of-treatment data from the Phase 2a clinical trial in patients receiving ongoing standard-of-care nucleoside analogue therapy indicating that treatment with imdusiran, Arbutus’ RNAi therapeutic, followed by Barinthus Biotherapeutic’s T-cell stimulating immunotherapeutic, VTP-300, was generally safe, well-tolerated and led to maintenance of lower HBsAg levels during the post-treatment follow-up period in patients with cHBV.

Arbutus Biopharma Corporation , today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 2024.